CD73: An emerging checkpoint for cancer immunotherapy

Siqi Chen, Derek Alan Wainwright, Jennifer D. Wu, Yong Wan, Daniela Elena Matei, Yi Zhang, Bin Zhang

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.

Original languageEnglish (US)
Pages (from-to)983-997
Number of pages15
JournalImmunotherapy
Volume11
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Immunotherapy
Neoplasms
Adenosine
Immunity
Carcinogenesis
Therapeutics

Keywords

  • CD73
  • adenosine receptor
  • immune checkpoint blockade
  • immunotherapy
  • tumor evasion

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

@article{5b9f37b676c04679be500c89f34ac726,
title = "CD73: An emerging checkpoint for cancer immunotherapy",
abstract = "CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.",
keywords = "CD73, adenosine receptor, immune checkpoint blockade, immunotherapy, tumor evasion",
author = "Siqi Chen and Wainwright, {Derek Alan} and Wu, {Jennifer D.} and Yong Wan and Matei, {Daniela Elena} and Yi Zhang and Bin Zhang",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2018-0200",
language = "English (US)",
volume = "11",
pages = "983--997",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "11",

}

CD73 : An emerging checkpoint for cancer immunotherapy. / Chen, Siqi; Wainwright, Derek Alan; Wu, Jennifer D.; Wan, Yong; Matei, Daniela Elena; Zhang, Yi; Zhang, Bin.

In: Immunotherapy, Vol. 11, No. 11, 01.01.2019, p. 983-997.

Research output: Contribution to journalReview article

TY - JOUR

T1 - CD73

T2 - An emerging checkpoint for cancer immunotherapy

AU - Chen, Siqi

AU - Wainwright, Derek Alan

AU - Wu, Jennifer D.

AU - Wan, Yong

AU - Matei, Daniela Elena

AU - Zhang, Yi

AU - Zhang, Bin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.

AB - CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.

KW - CD73

KW - adenosine receptor

KW - immune checkpoint blockade

KW - immunotherapy

KW - tumor evasion

UR - http://www.scopus.com/inward/record.url?scp=85068166704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068166704&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0200

DO - 10.2217/imt-2018-0200

M3 - Review article

C2 - 31223045

AN - SCOPUS:85068166704

VL - 11

SP - 983

EP - 997

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 11

ER -